Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome
Status:
Active, not recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalating safety study of the advanced therapy investigational
medicinal product (ATIMP) KI-MSC-PL-205, where patients diagnosed with SARS-CoV-2-induced
severe acute respiratory distress syndrome (ARDS), according to the Berlin Definition, and
who are on respirator/ventilator (used synonymously in this protocol) support due to
respiratory insufficiency with or without concomitant circulatory problems, will be included
and treated with a single dose of KI-MSC-PL-205.